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Key Points
• Nonanticoagulant heparin is
shown to bind histones and
provide cytoprotection in
mouse models of sterile
inflammation and sepsis.
Extracellular histones are considered to bemajormediators of death in sepsis. Although
sepsis is a condition that may benefit from low-dose heparin administration, medical
doctors need to take into consideration the potential bleeding risk in sepsis patients
who are already at increased risk of bleeding due to a consumption coagulopathy. Here,
we show that mechanisms that are independent of the anticoagulant properties of
heparin may contribute to the observed beneficial effects of heparin in the treatment of
sepsis patients. We show that nonanticoagulant heparin, purified from clinical grade
heparin, binds histones and prevents histone-mediated cytotoxicity in vitro and reduces
mortality from sterile inflammation and sepsis inmousemodels without increasing the risk of bleeding. Our results demonstrate that
administration of nonanticoagulant heparin is a novel and promising approach that may be further developed to treat patients
suffering from sepsis. (Blood. 2014;123(7):1098-1101)
Introduction
Sepsis and septic shock are serious clinical problems with high
mortality rates for which no adequate treatment currently exists.1
Neutrophils respond to infection with the formation of neutrophil
extracellular traps (NETs),2,3 intricate networks containing DNA
as the major structural component and proteins like histones and
neutrophil elastase, which have antimicrobial properties. Extra-
cellular histones, however, also exhibit cytotoxic activity toward
host cells, including the endothelium.4,5 Histone release can thus
trigger a feedback cascade, resulting in more cell death and additional
release of histones.6 Consequently, extracellular histones are consid-
ered interesting therapeutic targets for sepsis treatment.4
Histones are positively charged, and NET-mediated cytotoxicity
can be reduced with polysialic acid, a negatively charged polymer.5
We hypothesized that heparin, a negatively charged polysaccharide,
blocks histone cytotoxicity and reduces mortality from sterile in-
ﬂammation and sepsis. Low dose unfractionated heparin (UFH) has
been tested in a clinical trial as a complementary treatment of
sepsis.7 The study rationale linked infection, inﬂammation, and
coagulation in sepsis and sought to inhibit the coagulation part with
low doses of heparin so as not to increase the risk of bleeding in
a patient who is already at risk due to sepsis-associated consumption
coagulopathy.7,8 Nevertheless, although this study failed to dem-
onstrate a signiﬁcant beneﬁt on 28-day mortality rate, we hypoth-
esize that the minor beneﬁcial effects of heparin observed might
be attributed to a mechanism independent of the anticoagulant
properties of heparin. We reasoned that removing the anticoagulant
fraction from UFH would yield an antithrombin afﬁnity-depleted
heparin (AADH) that neutralizes histone-mediated cytotoxicity and
effectively treats sepsis without increasing risk of bleeding. Heparins
have the highest negative charge density of any known biological
molecule9 and have a strong afﬁnity for histones.10,11 It is, however,
not known whether binding of heparin to histones also protects
against the cytotoxic effect of histones on endothelial cells and/or in
vivo. Here, we investigated the effects of UFH and AADH on histone
cytotoxicity. We present data showing that complex formation of
histones with heparin reduces their cytotoxicity in an in vitro cell-
based cytotoxicity assay. Furthermore, by use of in vivo mouse
models of sterile inﬂammation, a cecal ligation and puncture
(CLP) model for sepsis and bacterial lipopolysaccharide (LPS)
challenge, we show that AADH increases the survival rate in all 3
animal models.
Study design
AADH was produced by fractionation of UFH via afﬁnity chromatography
using an antithrombin-column, and its anticoagulant properties were quan-
titated via calibrated automated thrombography (CAT). The cytotoxic
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effects of puriﬁed histones, in the presence of UFH and AADH, were
tested in vitro via a ﬂow cytometry-based histone cytotoxicity assay employing
EA.hy926 cells. Direct binding interaction between histones and AADH was
determined using surface plasmon resonance and confocal laser scanning
ﬂuorescence microscopy. In vivo, the activities of UFH and AADH were
tested in C57Bl6/J mice through a concanavalin A (ConA) challenge model
for fatal sterile inﬂammation, through a CLP model and an LPS challenge
model. Survival was used as the primary endpoint in these assays; liver
viability assessment was performed to correlate disease severity to organ
damage in the animals tested (CLP) and neutrophil lung inﬁltration, tissue
leakage, and bronchoalveolar lavage cytokine levels were determined in
the LPS model. Anticoagulant properties of administered UFH and AADH
were assessed via CAT and tail bleeding time measurements. Detailed
methods are given in the supplemental Data, available on the BloodWeb site.
The experiments were approved by the animal care committees of the Spanish
National Research Council and of the Ludwig-Maximilians-University Munich.
Results and discussion
Antithrombin afﬁnity chromatography yielded a fraction of UFH,
AADH, with strongly decreased anticoagulant activity12 (Figure 1A)
as determined by CAT,which shows that AADH has retained 0.2% to
0.5% of the anticoagulant activity of UFH. Both UFH and
AADH inhibited dose-dependently the cytotoxic activity of puriﬁed
histones in cell culture (Figure 1B-C). To analyze whether AADH
binds to histones, direct binding of AADH to histones was veriﬁed
by surface plasmon resonance (Figure 1D). Binding afﬁnity between
histone H3 and AADH was characterized by an apparent dis-
sociation constant of 86 nM. We further demonstrated in vitro,
employing isolated human neutrophils, that addition of AADH to
neutrophils that have produced NETs5 (supplemental Figure 1A)
results in colocalization of AADH with extracellular DNA ﬁbers
and histones (Figure 1E-F; supplemental Figure 1B-C). Thus,
both UFH and AADH possess cytoprotective properties, conferred
by complexation of histones, because we veriﬁed that heparin-histone
complexes are devoid of cytotoxic properties (supplemental
Figure 1D).
To further test our hypothesis on the cytoprotective activities of
AADH and translate our in vitro ﬁndings into an in vivo system, we
next evaluated the effects of AADH on the overall mortality rate in
a mouse model of fatal liver injury using ConA-triggered activation
of T cells to mimic sterile inﬂammation (Figure 2A). It has been
described that extracellular histones are the major mediators of death
in this model.13 We measured plasma levels of histone H3 by semi-
quantitative western blotting13 and showed that ConA injection
increased circulating histone H3 levels in all animals (Figure 2B). In
treated animals, appearance of histones was delayed and from our
in vitro studies and reported in vivo cytotoxicity of extracellular
histones, we conclude that histones detected in the treated group are
at least partly complexed to AADH. Injection of ConA caused
signiﬁcant differences in 24-hour survival between the AADH-
treated and control groups (P , .0005) (Figure 2A), with only a
moderate effect of AADH on thrombin formation (supplemental
Figure 1E). We veriﬁed that the moderate anticoagulant effect seen
is independent of any antithrombin-mediated activities of AADH
Figure 1. In vitro heparin characterization. (A) In vitro effects of varying amounts of UFH and AADH on thrombin generation in normal pooled mouse plasma as measured by
CAT.12 Variable amounts of UFH (B) or AADH (C) and histone H3 (H3) were added to EA.hy926 cells and cell viability was quantitated with flow cytometry. Each bar represents
the average6 SD of at least 5 independent experiments. (D) Surface plasmon resonance–analysis of AADH binding to immobilized histone H3 with collected data points in blue
and data fit in black. Saturation of binding was verified by analysis of the binding data (insert). (E-F) Fluorimaging analysis of phorbol myristate acetate–stimulated human
neutrophils stained with propidium iodide (red), FITC-labeled AADH (green), or anti-histone H2B antibody (blue). (E) A detail showing colocalization (yellow, arrow) of histones,
DNA, and AADH on extracellular DNA fibers. (F) Representative presentation of a larger field with NETs, where colocalization (yellow) was observed for histones, DNA, and
AADH. Arrows indicate several of the colocalization sites. Bar represents 20 mm for histology. Individual images for the composites (E-F) have been added as supplemental figures.
Statistical significance (P , .05) was tested using one-way analysis of variance with Dunnett post hoc test. *Indicates significant difference compared with control samples.
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Figure 2. In vivo effects of AADH. (A) Twenty-four–hour survival in mice challenged through intravenous injection of 30 mg/kg ConA following intraperitoneal injection of
570 mg AADH (n 5 15, dashed line) or saline (n 5 16, solid line). Found differences are significant (P 5 .0005, with hazard ratio 5 8.384 and 95% confidence interval (CI) of
ratio 2.371-21.79). (B) Plasma of saline- or AADH-treated mice was collected 3 or 6 hours after ConA challenge and pooled (n5 6). Histone H3 content was characterized by
western blotting. For comparison, a pooled mouse plasma sample from mice not challenged with ConA is shown. Relative densities as determined by densitometry using
ImageJ are indicated. (C) Seventy-two–hour survival in CLP-challenged C57Bl/6 mice treated by intraperitoneal injection with 570 mg AADH 12 hours before, directly after,
and 12 hours after CLP (prophylaxis, n 5 10, dashed black line) or only 4 hours after CLP (n 5 10, dashed gray line). Saline-treated, CLP-challenged mice are shown as
a solid black line (n 5 15), whereas survival of sham-treated animals is shown as a dotted gray line (n 5 15). Differences between AADH-treated and nontreated groups are
significant (for both the prophylactic and treatment regimes, with P 5 .0031 and P 5 .0275, respectively, and hazard ratios 5 5.471 and 3.345, 95% CI of ratio 1.774-16.87
and 1.143-9.787, respectively. (D-H) Effect of AADH in a mouse model of LPS-induced sepsis. C57Bl/6 mice were treated with LPS 20 mg/kg i.p. and 570 mg AADH after 1
hour of the LPS challenge. (D) Survival in mice receiving LPS and vehicle (solid line) and mice receiving LPS plus AADH (dashed line) (n5 9/group). The difference between
groups is significant, with P 5 .0375 and hazard ratio 5 5.4328 and 95% CI of ratio 1.088-17.22. (E-H) Mice were euthanized 8 hours after LPS challenge. (E) Representative
histological hematoxylin and eosin-stained sections of lungs from mice receiving saline (e1), LPS1 vehicle control (e2), or LPS1 AADH (e3). (F) Quantification of histological
analysis, n 5 4 per bar. (G) Quantification of neutrophils in the bronchoalveolar lavage (BAL) (white bars, left y-axis) of adherent, intravascular (black bars, right y-axis), and
interstitial (gray bars, right y-axis) neutrophils. Discrimination between neutrophils in either location was made based on an antibody to Ly6G injected 5 minutes prior to
euthanasia (n 5 6-8 for each bar). (H) Assessment of lung plasma leakage based on the exudation of the plasma tracer FITC dextran (n 5 6-8). Statistical significance was
tested using one-way analysis of variance with Dunnett post hoc test. *Indicates significant difference (P , .05) compared with the LPS-challenged group.
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and can be attributed to heparin cofactor II stimulation, the plasma
concentration of which does not allow complete inhibition of
thrombin formation.14 Together, our in vitro and in vivo results
strongly indicate that AADH treatment results in complexation and
inactivation of circulating histones with a concomitant improvement
of survival, in agreement with the observation that AADH abolished
cytotoxic effects of histones on endothelial cells by complexation
(supplemental Figure 1D). In contrast to UFH, AADH treatment of
unchallenged mice with a dose 5 times that of UFH caused only
moderate anticoagulation of blood plasma (supplemental Figure 1F)
and no signiﬁcant prolongation of tail bleeding time (supplemental
Figure 1G). Furthermore, AADH treatment had no signiﬁcant effects
on plasma levels of the cytokines interleukin-6, interleukin-10, and
tumor necrosis factor at 3 and 6 hours after ConA challenge (data not
shown).
To further investigate the potential therapeutic value of AADH,
we injected AADH in a mouse CLP model known to mimic human
sepsis15 and an LPS injection model that mimics TLR-mediated
septic shock.15 As observed in the ConA model, AADH is able to
signiﬁcantly increase survival both when given prior to cecal punc-
ture as well as when given 4 hours after puncture (Figure 2C) and
when given 1 hour after LPS challenge (Figure 2D). Protection of
organs is likely to contribute to overall survival as was concluded
from a liver viability assessment after CLP (supplemental Figure 1H)
and lung tissue histological analysis (Figure 2E). Administration of
AADH appears to reduce neutrophil inﬂux, protects against intra-
pulmonary protein leakage and capillary-alveolar leakage, and is
accompanied by reduction of cytokine release (Figure 2F-G; sup-
plemental Figure 1I-J).
We conclude that AADH, a low anticoagulant fraction of UFH,
has therapeutic potential to treat sepsis and other hyperinﬂamma-
tory conditions in which excessive neutrophil activation with re-
lease of histones is part of the host response. Given the huge clinical
experience with UFH and the anticipated safe proﬁle of AADH, we
expect low thresholds for commencing clinical studies in the near
future.
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